Arkolith/Insider Trading/KNSA/Form 4

Quart Barry D

DirectorKiniksa Pharmaceuticals International, plc (KNSA) · full profile →Form 4 · filed Dec 17, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$836K
Net Open-Market Flow
-$836K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 15, 2025Sell(S)20K$41.51$836K13K
Dec 15, 2025Option exercise(M)20K$10.36$209K33K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 15, 2025Option exercise(M)20K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001384243-25-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML